You can buy or sell BeyondSpring and other stocks, options, ETFs, and crypto commission-free!
BeyondSpring Inc. Ordinary Shares, also called BeyondSpring, is a clinical stage company, which engages in the development of cancer therapies. Read More It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results from this non-clinical study will be highlighted in a poster presentation titled, “Pre...
Markets InsiderMar 20
BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will present clinical data on its lead asset, Plinabulin, during a poster presentation at the 2019 St. Gallen International Breast Cancer Conference, being held on March 20 through 23 in Vienna, Austria. Abstract P017 Title: “A Randomized Clinical Trial of the Combination of Plinabulin (Plin) + Pegfil...
Seeking AlphaFeb 26
BeyondSpring's Plinabulin shows positive action in mid-stage breast cancer study
New data from a Phase 2 clinical trial, Study 106, evaluating BeyondSpring's (BYSI +0.1% ) lead drug Plinabulin compared to Amgen's (AMGN +0.1% ) Neulasta (pegfilgrastim) in reducing the duration of severe neutropenia (abnormally low levels of a type of white blood cell) in certain breast cancer patients showed a positive effect.
-$0.56 per share
Expected Mar 26, Pre-Market